Cara's IV analgesic meets in Phase III for postoperative pain

Cara Therapeutics Inc. (NASDAQ:CARA) said IV CR845 met the primary and secondary endpoints in the adaptive Phase II/III CLIN3001 trial to treat postoperative pain in patients undergoing abdominal surgery.

On the primary endpoint, the 1 µg/kg dose of IV CR845 significantly improved pain relief as measured by area under the curve (AUC) of the Numeric Rating Scale (NRS) over 24 hours postsurgery vs. placebo (p=0.032). A 0.5 µg/kg dose of IV CR845 missed the primary endpoint vs. placebo (p=0.076)...